Latest Hospira Inc (HSP) Headlines Shares of HS
Post# of 48
Posted On: 03/14/2014 3:52:09 PM
Latest Hospira Inc (HSP) Headlines
Shares of HSP Up 31.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Mar 14, 9:16AM CDT
SmarTrend identified an Uptrend for Hospira (NYSE:HSP) on March 20th, 2013 at $32.32. In approximately 12 months, Hospira has returned 31.16% as of today's recent price of $42.39.
Trade-Ideas: Hospira (HSP) Is Today's "Water-Logged And Getting Wetter" Stock
at The Street - Tue Mar 11, 1:30PM CDT
Trade-Ideas LLC identified Hospira (HSP) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
The Growth Driver Johnson & Johnson Investors Need to Watch
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 07, 1:30PM CST
Healthcare giant Johnson & Johnson is one of the most diversified companies in the industry. While many identify the company with its notable consumer brands, which include Band-Aid and Neutrogena products,it always seems to have a steady...
Uptrend Call Working As Hospira Stock Rises 34.7% (HSP)
Comtex SmarTrend(R) - Thu Mar 06, 5:01PM CST
SmarTrend identified an Uptrend for Hospira (NYSE:HSP) on March 20th, 2013 at $32.32. In approximately 12 months, Hospira has returned 34.68% as of today's recent price of $43.53.
3 Big Battles in Biosimilars to Watch
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 05, 1:30PM CST
The global market for biosimilars, or generic versions of biologic medical products, is expected to soar to $24 billion by 2019, according to a recent report from Frost & Sullivan -- not bad for a fledgling industry that currently only consists...
Hospira elects David J Endicott as president of Hospira Medical Devices
M2 - Wed Mar 05, 5:24AM CST
US-based drugs company Hospira (NYSE:HSP) revealed on Tuesday the appointment of David J Endicott as president of Hospira Medical Devices as well as a member of its senior leadership team, reporting directly to its CEO F. Michael Ball.
Hospira Names David J. Endicott President of Medical Devices
PR Newswire - Tue Mar 04, 8:34AM CST
Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that David J. Endicott has been named President, Hospira Medical Devices, effective March 10, 2014. In this newly created role, Mr. Endicott will have responsibility for establishing a fully integrated device organization - leading the commercial, research and development, manufacturing and related support functions to continue to advance the company's product pipeline, execute its device strategy and ultimately drive global growth. He will serve as a member of Hospira's senior leadership team and report directly to F. Michael Ball, chief executive officer.
Form 4: Update Filing for Hospira Inc (HSP)
Vickers Stock Research - Sat Mar 01, 8:58AM CST
NOVA Chemicals Corporation, 1000 Seventh Avenue S.W., Calgary, Alberta, Canada T2P 5L5
Even With Growth Opportunities Ahead, Is Hospira Overvalued?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Feb 27, 1:30PM CST
Leading specialty injectables and infusion pump manufacturer Hospira has suffered greatly from largely self-inflicted wounds over the past couple of years. A lackadaisical approach to proper plant management has led to numerous FDA warning letters...
33.0% Return Seen to Date on SmarTrend Hospira Call (HSP)
Comtex SmarTrend(R) - Thu Feb 27, 11:06AM CST
SmarTrend identified an Uptrend for Hospira (NYSE:HSP) on March 20th, 2013 at $32.32. In approximately 11 months, Hospira has returned 33.01% as of today's recent price of $42.99.
Will Hospira's Lack of a Dividend Hold It Back in 2014?
Peter Stephens, The Motley Fool - Motley Fool - Fri Feb 21, 6:22PM CST
As all Foolish investors know, dividends are often a key part of an investment portfolio. Indeed, numerous pieces of research over the years have shown that dividends, when reinvested, tend to make up a significant proportion, if not the majority, of...
Hospira Falls 3.89% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Feb 21, 4:34PM CST
Hospira (NYSE:HSP) traded in a range yesterday that spanned from a low of $41.86 to a high of $43.90. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $43.59 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Hospira After 3.89% Loss
Comtex SmarTrend(R) - Fri Feb 21, 4:34PM CST
Hospira (NYSE:HSP) traded in a range yesterday that spanned from a low of $41.86 to a high of $43.90. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $43.59 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
APNewsBreak: Where Ohio got its execution drugs
By ANDREW WELSH-HUGGINS - AP - Thu Feb 20, 10:35AM CST
COLUMBUS, Ohio (AP) — Ohio's most recent batches of lethal injection drugs were produced by a company that wants states to stop using them for capital punishment, records show.
Hospira Shares Up 35.6% Since SmarTrend's Buy Recommendation (HSP)
Comtex SmarTrend(R) - Thu Feb 20, 9:38AM CST
SmarTrend identified an Uptrend for Hospira (NYSE:HSP) on March 20th, 2013 at $32.32. In approximately 11 months, Hospira has returned 35.55% as of today's recent price of $43.81.
Bear Naked® One Ups The Granola Scene With Debut Of Honey Almond Protein Flavor
PR Newswire - Wed Feb 19, 6:02AM CST
Fueling a passion to satisfy everyday adventurers, Bear Naked® granola is introducing a new naturally delicious flavor--Honey Almond Protein - made with immensely tasty soft-baked whole-grain oats, sweet honey and full roasted almonds. With 10 grams of protein per serving, Bear Naked Honey Almond Protein is the perfect on-the-go snack to nourish adventure-seekers who want to take their winter experiences to the next level.
EU's stance forces US executioners to improvise
By JUERGEN BAETZ - AP - Tue Feb 18, 1:22PM CST
BRUSSELS (AP) — There's one big reason the United States has a dearth of execution drugs so acute that some states are considering solutions such as firing squads and gas chambers: Europe won't allow the drugs to be exported because of its fierce hostility to capital punishment.
Marginal Earnings Beat at Hospira in Q4 (Revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 10:20AM CST
Hospira's fourth quarter 2013 adjusted earnings of 51 cents per share surpassed the Zacks Consensus Estimate by a penny.
Shares of HSP Up 31.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Mar 14, 9:16AM CDT
SmarTrend identified an Uptrend for Hospira (NYSE:HSP) on March 20th, 2013 at $32.32. In approximately 12 months, Hospira has returned 31.16% as of today's recent price of $42.39.
Trade-Ideas: Hospira (HSP) Is Today's "Water-Logged And Getting Wetter" Stock
at The Street - Tue Mar 11, 1:30PM CDT
Trade-Ideas LLC identified Hospira (HSP) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Appointments, Financial Reports, and FDA Approvals - Analyst Notes on Hospira, Karyopharm, Revance, Pluristem, and Sunesis
PR Newswire - Tue Mar 11, 8:19AM CDT
Today, Analysts Review released its analysts' notes regarding Hospira Inc. (NYSE: HSP), Karyopharm Therapeutics, Inc. (NASDAQ: KPTI), Revance Therapeutics, Inc. (NASDAQ: RVNC), Pluristem Therapeutics, Inc. (NASDAQ: PSTI), and Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
The Growth Driver Johnson & Johnson Investors Need to Watch
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 07, 1:30PM CST
Healthcare giant Johnson & Johnson is one of the most diversified companies in the industry. While many identify the company with its notable consumer brands, which include Band-Aid and Neutrogena products,it always seems to have a steady...
Uptrend Call Working As Hospira Stock Rises 34.7% (HSP)
Comtex SmarTrend(R) - Thu Mar 06, 5:01PM CST
SmarTrend identified an Uptrend for Hospira (NYSE:HSP) on March 20th, 2013 at $32.32. In approximately 12 months, Hospira has returned 34.68% as of today's recent price of $43.53.
3 Big Battles in Biosimilars to Watch
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 05, 1:30PM CST
The global market for biosimilars, or generic versions of biologic medical products, is expected to soar to $24 billion by 2019, according to a recent report from Frost & Sullivan -- not bad for a fledgling industry that currently only consists...
Hospira elects David J Endicott as president of Hospira Medical Devices
M2 - Wed Mar 05, 5:24AM CST
US-based drugs company Hospira (NYSE:HSP) revealed on Tuesday the appointment of David J Endicott as president of Hospira Medical Devices as well as a member of its senior leadership team, reporting directly to its CEO F. Michael Ball.
Hospira Names David J. Endicott President of Medical Devices
PR Newswire - Tue Mar 04, 8:34AM CST
Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that David J. Endicott has been named President, Hospira Medical Devices, effective March 10, 2014. In this newly created role, Mr. Endicott will have responsibility for establishing a fully integrated device organization - leading the commercial, research and development, manufacturing and related support functions to continue to advance the company's product pipeline, execute its device strategy and ultimately drive global growth. He will serve as a member of Hospira's senior leadership team and report directly to F. Michael Ball, chief executive officer.
Form 4: Update Filing for Hospira Inc (HSP)
Vickers Stock Research - Sat Mar 01, 8:58AM CST
NOVA Chemicals Corporation, 1000 Seventh Avenue S.W., Calgary, Alberta, Canada T2P 5L5
Even With Growth Opportunities Ahead, Is Hospira Overvalued?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Feb 27, 1:30PM CST
Leading specialty injectables and infusion pump manufacturer Hospira has suffered greatly from largely self-inflicted wounds over the past couple of years. A lackadaisical approach to proper plant management has led to numerous FDA warning letters...
33.0% Return Seen to Date on SmarTrend Hospira Call (HSP)
Comtex SmarTrend(R) - Thu Feb 27, 11:06AM CST
SmarTrend identified an Uptrend for Hospira (NYSE:HSP) on March 20th, 2013 at $32.32. In approximately 11 months, Hospira has returned 33.01% as of today's recent price of $42.99.
Will Hospira's Lack of a Dividend Hold It Back in 2014?
Peter Stephens, The Motley Fool - Motley Fool - Fri Feb 21, 6:22PM CST
As all Foolish investors know, dividends are often a key part of an investment portfolio. Indeed, numerous pieces of research over the years have shown that dividends, when reinvested, tend to make up a significant proportion, if not the majority, of...
Hospira Falls 3.89% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Feb 21, 4:34PM CST
Hospira (NYSE:HSP) traded in a range yesterday that spanned from a low of $41.86 to a high of $43.90. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $43.59 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Hospira After 3.89% Loss
Comtex SmarTrend(R) - Fri Feb 21, 4:34PM CST
Hospira (NYSE:HSP) traded in a range yesterday that spanned from a low of $41.86 to a high of $43.90. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $43.59 on volume of 3.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
APNewsBreak: Where Ohio got its execution drugs
By ANDREW WELSH-HUGGINS - AP - Thu Feb 20, 10:35AM CST
COLUMBUS, Ohio (AP) — Ohio's most recent batches of lethal injection drugs were produced by a company that wants states to stop using them for capital punishment, records show.
Hospira Shares Up 35.6% Since SmarTrend's Buy Recommendation (HSP)
Comtex SmarTrend(R) - Thu Feb 20, 9:38AM CST
SmarTrend identified an Uptrend for Hospira (NYSE:HSP) on March 20th, 2013 at $32.32. In approximately 11 months, Hospira has returned 35.55% as of today's recent price of $43.81.
Bear Naked® One Ups The Granola Scene With Debut Of Honey Almond Protein Flavor
PR Newswire - Wed Feb 19, 6:02AM CST
Fueling a passion to satisfy everyday adventurers, Bear Naked® granola is introducing a new naturally delicious flavor--Honey Almond Protein - made with immensely tasty soft-baked whole-grain oats, sweet honey and full roasted almonds. With 10 grams of protein per serving, Bear Naked Honey Almond Protein is the perfect on-the-go snack to nourish adventure-seekers who want to take their winter experiences to the next level.
EU's stance forces US executioners to improvise
By JUERGEN BAETZ - AP - Tue Feb 18, 1:22PM CST
BRUSSELS (AP) — There's one big reason the United States has a dearth of execution drugs so acute that some states are considering solutions such as firing squads and gas chambers: Europe won't allow the drugs to be exported because of its fierce hostility to capital punishment.
Marginal Earnings Beat at Hospira in Q4 (Revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 10:20AM CST
Hospira's fourth quarter 2013 adjusted earnings of 51 cents per share surpassed the Zacks Consensus Estimate by a penny.
(0)
(0)Hospira Inc (HSP) Stock Research Links
Scroll down for more posts ▼